Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:SVRA

Savara Q3 2024 Earnings Report

Savara logo
$5.07 +0.07 (+1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$5.08 +0.00 (+0.10%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Savara EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.11
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Savara Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Savara Announcement Details

Quarter
Q3 2024
Date
11/12/2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Savara's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Savara's Q3 2024 Press ReleasePress Release
(8-K)
Savara's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Savara Earnings Headlines

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?
September 24 at 1:47 PM  |  rttnews.comhttps://www.rttnews.com/3693699/savara-awaits-fda-verdict-will-molbreevi-pass-regulatory-muster.aspx
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...
August 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-encore-presentations-results-200500773.html
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about what $375,000 did five years ago, even though no statement shows the change. Central banks have bought over 1,000 tonnes of gold a year for three straight years, using the same published data now explained in a free guide. The guide breaks down what's driving the shift in plain English, so readers can see the numbers for themselves.tc pixel
September 24 at 1:00 AM  |  American Alternative (Ad)
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
August 24, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260824428528/en/savara-announces-encore-presentations-of-results-from-the-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-at-the-european-respiratory-society-ers-congress-2026/
Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SVRA/press-releases/
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930599-savara-high-potential-binary-bet-cruising-to-pdufa-after-3-month-speed-bump
See More Savara Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email.

About Savara

Savara (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs. Savara has evaluated molgramostim in clinical trials for aPAP and has pursued regulatory approval in the United States and other markets.

The company was established as a specialty pharmaceutical business and later shifted its strategy toward rare respiratory diseases, including through its acquisition of Parion Sciences’ respiratory drug development programs. Savara is headquartered in Austin, Texas, and conducts development activities through clinical and regulatory programs in the United States and internationally. Matthew Pauls has served as the company’s president and chief executive officer.

View Savara Profile
Earnings Tools